biotech

FDA Approves Lucentis For Age-Related Vision Loss

Filed in archive Drugs, Vaccines and Therapeutics on July 3, 2006

FDA Approves Lucentis For Age-Related Vision Loss
After a 6-month priority review, the U.S. Food and Drug Administration (FDA) has approved Genentech's drug against age-related macular degeneration (AMD). LUCENTISâ„¢ (ranibizumab) is an antibody fragment which works by binding and inhibiting Vascular Endothelial Growth Factor, VEGF-A, a protein that is believed to play a critical role in angiogenesis (the formation of new blood vessels). It will be administered via monthly intravitreal injections.

Genetech officials say Lccentis is the first therapy to improve vision in wet AMD patients. Highlights of the pivotal clinical studies that led to this approval are discussed in the company press release. A reply of a webcast by the Genentech management on the approval may be accessed until July 7 at the company website. Access numbers for this replay are: 1-800-642-1687 (U.S./Canada) and 1-706-645-9291 (international); Conference ID number is 1794492.

Permalink: FDA Approves Lucentis For Age-Related Vision Loss

Tags: vision  blindness  biotech  related  approves  approves+lucentis  related+vision  vision+loss 

Vote for FDA Approves Lucentis For Age-Related Vision Loss:

  • Currently 8.67/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 8.67 out of 3 vote(s) cast.
 
Share It
RSSrss
Google google
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Most Popular   Best of   Biotech Hubs and Facilities   Biotech/Science Blogs   Corporate and Industrial News   Diagnostics, Methodologies and Instrumentation   Did you know   Drugs, Vaccines and Therapeutics   Energy, Environment and Ecology   Food and Agriculture   Gene Therapy   Genomics, Proteomics and Bioinformatics   Information About   Meetings and Other Events   Microbiology   Misc   Nanomedicine   Other Biotechnology News   Patents and Intellectual Property Rights   Quick introduction   Stem Cells